TABLE 5.
Setting 2, : Measures of size of the trial across scenarios, total duration in weeks, and total number of patients
| TITE‐CRM | TITE‐CRM2 | ICSDP | POMM | nTTP | TITE‐BOIN | TITE‐mTPI2 | R‐mTPI2 | |
|---|---|---|---|---|---|---|---|---|
| Scenario | Mean duration in weeks (SD) | |||||||
| A | 39 (13) | 31 (13) | 44 (12) | 44 (13) | 29 (4) | 33 (18) | 41 (26) | 43 (30) |
| B | 52 (12) | 50 (16) | 53 (10) | 45 (9) | 32 (6) | 51 (17) | 78 (32) | 90 (38) |
| C | 32 (13) | 25 (11) | 38 (14) | 39 (15) | 27 (5) | 27 (19) | 32 (25) | 29 (27) |
| D | 57 (9) | 50 (10) | 49 (5) | 36 (7) | 29 (5) | 40 (7) | 76 (10) | 92 (12) |
| Mean | 45 | 39 | 46 | 41 | 29 | 38 | 57 | 63 |
| Scenario | Mean number of patients (SD) | |||||||
| A | 14 (6) | 10 (6) | 16 (6) | 17 (6) | 9 (2) | 16 (8) | 13 (7) | 12 (7) |
| B | 20 (6) | 19 (8) | 21 (5) | 17 (4) | 10 (3) | 24 (7) | 20 (7) | 22 (8) |
| C | 11 (6) | 8 (5) | 14 (6) | 14 (7) | 8 (2) | 13 (9) | 10 (7) | 9 (6) |
| D | 23 (5) | 20 (4) | 19 (3) | 13 (3) | 10 (2) | 20 (3) | 20 (3) | 21 (3) |
| Mean | 17 | 14 | 17 | 15 | 9 | 18 | 16 | 16 |